{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T02:13:27Z","timestamp":1794276807319,"version":"4.9.0"},"reference-count":77,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2023,10,21]],"date-time":"2023-10-21T00:00:00Z","timestamp":1697846400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,10,21]],"date-time":"2023-10-21T00:00:00Z","timestamp":1697846400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Psychiatry Rep"],"published-print":{"date-parts":[[2023,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose of Review<\/jats:title>\n                <jats:p>Despite clear evidence that sex differences largely impact the efficacy and tolerability of antipsychotic medication, current treatment guidelines for schizophrenia spectrum disorders (SSD) do not differentiate between men and women. This review summarizes the available evidence on strategies that may improve pharmacotherapy for women and provides evidence-based recommendations to optimize treatment for women with schizophrenia.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Recent Findings<\/jats:title>\n                <jats:p>We systematically searched PubMed and Embase for peer-reviewed studies on three topics: (1) sex differences in dose-adjusted antipsychotic serum concentrations, (2) hormonal augmentation therapy with estrogen and estrogen-like compounds to improve symptom severity, and (3) strategies to reduce antipsychotic-induced hyperprolactinemia. Based on three database studies and one RCT, we found higher dose-adjusted concentrations in women compared to men for most antipsychotics. For quetiapine, higher concentrations were specifically found in older women. Based on two recent meta-analyses, both estrogen and raloxifene improved overall symptomatology. Most consistent findings were found for raloxifene augmentation in postmenopausal women. No studies evaluated the effects of estrogenic contraceptives on symptoms. Based on two meta-analyses and one RCT, adjunctive aripiprazole was the best-studied and safest strategy for lowering antipsychotic-induced hyperprolactinemia.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Summary<\/jats:title>\n                <jats:p>Evidence-based recommendations for female-specific pharmacotherapy for SSD consist of (1) female-specific dosing for antipsychotics (guided by therapeutic drug monitoring), (2) hormonal replacement with raloxifene in postmenopausal women, and (3) aripiprazole addition as best evidenced option in case of antipsychotic-induced hyperprolactinemia. Combining these strategies could reduce side effects and improve outcome of women with SSD, which should be confirmed in future longitudinal RCTs.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s11920-023-01460-6","type":"journal-article","created":{"date-parts":[[2023,10,21]],"date-time":"2023-10-21T06:01:33Z","timestamp":1697868093000},"page":"723-733","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Evidence-Based Recommendations for the Pharmacological Treatment of Women with Schizophrenia Spectrum Disorders"],"prefix":"10.1007","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2383-0851","authenticated-orcid":false,"given":"Bodyl A.","family":"Brand","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elske J. M.","family":"Willemse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iris M. H.","family":"Hamers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iris E.","family":"Sommer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,10,21]]},"reference":[{"issue":"9618","key":"1460_CR1","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1016\/S0140-6736(08)60486-9","volume":"371","author":"RS Kahn","year":"2008","unstructured":"Kahn RS, Fleischhacker WW, Boter H, et al. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet. 2008;371(9618):1085\u201397. https:\/\/doi.org\/10.1016\/S0140-6736(08)60486-9.","journal-title":"Lancet"},{"key":"1460_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/J.PSYCHRES.2019.112510","author":"N Thomas","year":"2019","unstructured":"Thomas N, Gurvich C, Hudaib AR, Gavrilidis E, Kulkarni J. Dissecting the syndrome of schizophrenia: associations between symptomatology and hormone levels in women with schizophrenia. Psychiatry Res. 2019. https:\/\/doi.org\/10.1016\/J.PSYCHRES.2019.112510.","journal-title":"Psychiatry Res"},{"key":"1460_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-1781(00)00161-X","author":"K Thompson","year":"2000","unstructured":"Thompson K, Sergejew A, Kulkarni J. Estrogen affects cognition in women with psychosis. Psychiatry Res. 2000. https:\/\/doi.org\/10.1016\/S0165-1781(00)00161-X.","journal-title":"Psychiatry Res"},{"issue":"5","key":"1460_CR4","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1093\/schbul\/sbn023","volume":"35","author":"MV Seeman","year":"2009","unstructured":"Seeman MV. Secondary effects of antipsychotics: women at greater risk than men. Schizophr Bull. 2009;35(5):937\u201348. https:\/\/doi.org\/10.1093\/schbul\/sbn023.","journal-title":"Schizophr Bull"},{"key":"1460_CR5","doi-asserted-by":"publisher","unstructured":"Riecher-R\u00f6ssler A. Estrogens and schizophrenia. In: Estrogen Effects in Psychiatric Disorders. Springer-Verlag; 2005:31\u201352. https:\/\/doi.org\/10.1007\/3-211-27063-9_2.","DOI":"10.1007\/3-211-27063-9_2"},{"key":"1460_CR6","doi-asserted-by":"publisher","DOI":"10.1007\/BF02190244","author":"A Riecher-R\u00f6ssler","year":"1993","unstructured":"Riecher-R\u00f6ssler A, H\u00e4fner H. Schizophrenia and oestrogens - is there an association? Eur Arch Psychiatry Clin Neurosci. 1993. https:\/\/doi.org\/10.1007\/BF02190244.","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"1460_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/0920-9964(92)90146-v","author":"A Riecher-R\u00f6ssler","year":"1992","unstructured":"Riecher-R\u00f6ssler A, H\u00e4fner H, Maurer K, Stummbaum M, Schmidt R. Schizophrenic symptomatology varies with serum estradiol levels during menstrual cycle. Schizophr Res. 1992. https:\/\/doi.org\/10.1016\/0920-9964(92)90146-v.","journal-title":"Schizophr Res"},{"key":"1460_CR8","unstructured":"NICE. Core interventions in the treatment and management of schizophrenia in adults in primary and secondary care. 2014. http:\/\/www.nice.org.uk\/guidance\/cg178. Accessed 12 Apr 2021."},{"issue":"1","key":"1460_CR9","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1093\/SCHBUL\/SBP130","volume":"36","author":"J Kreyenbuhl","year":"2010","unstructured":"Kreyenbuhl J, Buchanan RW, Dickerson FB, Dixon LB. The schizophrenia patient outcomes research team (PORT): updated treatment recommendations 2009. Schizophr Bull. 2010;36(1):94\u2013103. https:\/\/doi.org\/10.1093\/SCHBUL\/SBP130.","journal-title":"Schizophr Bull"},{"issue":"4","key":"1460_CR10","doi-asserted-by":"publisher","first-page":"379","DOI":"10.3109\/09540261.2011.606801","volume":"23","author":"W Gaebel","year":"2011","unstructured":"Gaebel W, Riesbeck M, Wobrock T. Schizophrenia guidelines across the world: a selective review and comparison. Int Rev Psychiatry. 2011;23(4):379\u201387. https:\/\/doi.org\/10.3109\/09540261.2011.606801.","journal-title":"Int Rev Psychiatry"},{"key":"1460_CR11","doi-asserted-by":"publisher","DOI":"10.1136\/BMJ.G1173","author":"E Kuipers","year":"2014","unstructured":"Kuipers E, Yesufu-Udechuku A, Taylor C, Kendall T. Management of psychosis and schizophrenia in adults: summary of updated NICE guidance. BMJ. 2014. https:\/\/doi.org\/10.1136\/BMJ.G1173.","journal-title":"BMJ"},{"issue":"9","key":"1460_CR12","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1177\/0706743717720196","volume":"62","author":"D Crockford","year":"2017","unstructured":"Crockford D, Addington D. Canadian schizophrenia guidelines: schizophrenia and other psychotic disorders with coexisting substance use disorders. Can J Psychiatry. 2017;62(9):624\u201334. https:\/\/doi.org\/10.1177\/0706743717720196.","journal-title":"Can J Psychiatry"},{"issue":"4","key":"1460_CR13","doi-asserted-by":"publisher","first-page":"303","DOI":"10.22365\/JPSYCH.2018.294.303","volume":"29","author":"M Hadjulis","year":"2018","unstructured":"Hadjulis M, Margariti M, Lazaridou M, et al. Clinical guidelines for the management of schizophrenia: pharmacological and psychological interventions (III). Psychiatriki. 2018;29(4):303\u201315. https:\/\/doi.org\/10.22365\/JPSYCH.2018.294.303.","journal-title":"Psychiatriki"},{"issue":"10202","key":"1460_CR14","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/S0140-6736(19)31135-3","volume":"394","author":"M Huhn","year":"2019","unstructured":"Huhn M, Nikolakopoulou A, Schneider-Thoma J, et al. Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. Lancet. 2019;394(10202):939\u201351. https:\/\/doi.org\/10.1016\/S0140-6736(19)31135-3.","journal-title":"Lancet"},{"key":"1460_CR15","unstructured":"Alexopoulos GS, Streim J, Carpenter D, Docherty JP. Using antipsychotic agents in older patients. J Clin Psychiatry. 2004;65(Suppl 2)."},{"issue":"9","key":"1460_CR16","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1177\/0706743717720195","volume":"62","author":"T Lecomte","year":"2017","unstructured":"Lecomte T, Abidi S, Garcia-Ortega I, et al. Canadian treatment guidelines on psychosocial treatment of schizophrenia in children and youth. Can J Psychiatry. 2017;62(9):648\u201355. https:\/\/doi.org\/10.1177\/0706743717720195.","journal-title":"Can J Psychiatry"},{"issue":"4","key":"1460_CR17","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1017\/S0033291721004591","volume":"52","author":"BA Brand","year":"2022","unstructured":"Brand BA, Haveman YRA, De Beer F, De Boer JN, Dazzan P, Sommer IEC. Antipsychotic medication for women with schizophrenia spectrum disorders. Psychol Med. 2022;52(4):649\u201363. https:\/\/doi.org\/10.1017\/S0033291721004591.","journal-title":"Psychol Med"},{"key":"1460_CR18","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.pnpbp.2017.11.004","volume":"82","author":"TSJ Iversen","year":"2018","unstructured":"Iversen TSJ, Steen NE, Dieset I, et al. Side effect burden of antipsychotic drugs in real life \u2013 impact of gender and polypharmacy. Prog Neuropsychopharmacol Biol Psychiatry. 2018;82:263\u201371. https:\/\/doi.org\/10.1016\/j.pnpbp.2017.11.004.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"9","key":"1460_CR19","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1176\/APPI.AJP.2020.177901","volume":"177","author":"GA Keepers","year":"2020","unstructured":"Keepers GA, Fochtmann LJ, Anzia JM, et al. The American Psychiatric Association practice guideline for the treatment of patients with schizophrenia. Am J Psychiatry. 2020;177(9):868\u201372. https:\/\/doi.org\/10.1176\/APPI.AJP.2020.177901.","journal-title":"Am J Psychiatry"},{"issue":"8","key":"1460_CR20","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1177\/0020764020934827","volume":"66","author":"A Ventriglio","year":"2020","unstructured":"Ventriglio A, Ricci F, Magnifico G, et al. Psychosocial interventions in schizophrenia: focus on guidelines. Int J Soc Psychiatry. 2020;66(8):735\u201347. https:\/\/doi.org\/10.1177\/0020764020934827.","journal-title":"Int J Soc Psychiatry"},{"key":"1460_CR21","doi-asserted-by":"publisher","first-page":"100743","DOI":"10.1016\/j.yfrne.2019.03.002","volume":"53","author":"J Kulkarni","year":"2019","unstructured":"Kulkarni J, Butler S, Riecher-R\u00f6ssler A. Estrogens and SERMS as adjunctive treatments for schizophrenia. Front Neuroendocrinol. 2019;53:100743. https:\/\/doi.org\/10.1016\/j.yfrne.2019.03.002.","journal-title":"Front Neuroendocrinol"},{"key":"1460_CR22","doi-asserted-by":"publisher","unstructured":"\u2022 Reilly TJ, Sagnay de la Bastida VC, Joyce DW, Cullen AE, McGuire P. Exacerbation of psychosis during the perimenstrual phase of the menstrual cycle: systematic review and meta-analysis. Schizophr Bull. 2020;46(1):78\u201390. https:\/\/doi.org\/10.1093\/schbul\/sbz030. This systematic review and meta-analysis showed that psychotic admission rates are significantly higher than expected during the perimenstrual phase of the menstrual cycle.","DOI":"10.1093\/schbul\/sbz030"},{"issue":"1","key":"1460_CR23","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/S2215-0366(16)30379-0","volume":"4","author":"A Riecher-R\u00f6ssler","year":"2017","unstructured":"Riecher-R\u00f6ssler A. Oestrogens, prolactin, hypothalamic-pituitary-gonadal axis, and schizophrenic psychoses. Lancet Psychiatry. 2017;4(1):63\u201372. https:\/\/doi.org\/10.1016\/S2215-0366(16)30379-0.","journal-title":"Lancet Psychiatry"},{"key":"1460_CR24","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/sbac139","author":"IE Sommer","year":"2022","unstructured":"Sommer IE, Brand BA, Gangadin S, Tanskanen A, Tiihonen J, Taipale H. Women with schizophrenia-spectrum disorders after menopause: a vulnerable group for relapse. Schizophr Bull. 2022. https:\/\/doi.org\/10.1093\/schbul\/sbac139.","journal-title":"Schizophr Bull"},{"issue":"2\u20133","key":"1460_CR25","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.schres.2012.08.016","volume":"141","author":"MJH Begemann","year":"2012","unstructured":"Begemann MJH, Dekker CF, van Lunenburg M, Sommer IE. Estrogen augmentation in schizophrenia: a quantitative review of current evidence. Schizophr Res. 2012;141(2\u20133):179\u201384. https:\/\/doi.org\/10.1016\/j.schres.2012.08.016.","journal-title":"Schizophr Res"},{"issue":"3","key":"1460_CR26","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/j.schres.2015.04.002","volume":"168","author":"SM Heringa","year":"2015","unstructured":"Heringa SM, Begemann MJH, Goverde AJ, Sommer IEC. Sex hormones and oxytocin augmentation strategies in schizophrenia: a quantitative review. Schizophr Res. 2015;168(3):603\u201313. https:\/\/doi.org\/10.1016\/j.schres.2015.04.002.","journal-title":"Schizophr Res"},{"key":"1460_CR27","doi-asserted-by":"publisher","DOI":"10.1007\/s11920-019-1095-z","author":"CA Lewis","year":"2019","unstructured":"Lewis CA, Kimmig ACS, Zsido RG, Jank A, Derntl B, Sacher J. Effects of hormonal contraceptives on mood: a focus on emotion recognition and reactivity, reward processing, and stress response. Curr Psychiatry Rep. 2019. https:\/\/doi.org\/10.1007\/s11920-019-1095-z.","journal-title":"Curr Psychiatry Rep"},{"issue":"1","key":"1460_CR28","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1158\/1940-6207.CAPR-19-0393","volume":"13","author":"PF Pinsky","year":"2020","unstructured":"Pinsky PF, Miller EA, Heckman-Stoddard BM, Minasian L. Breast cancer characteristics and survival among users versus nonusers of raloxifene. Cancer Prev Res. 2020;13(1):83\u201390. https:\/\/doi.org\/10.1158\/1940-6207.CAPR-19-0393.","journal-title":"Cancer Prev Res"},{"issue":"2","key":"1460_CR29","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1056\/NEJMoa062462","volume":"355","author":"E Barrett-Connor","year":"2006","unstructured":"Barrett-Connor E, Mosca L, Collins P, et al. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med. 2006;355(2):125\u201337. https:\/\/doi.org\/10.1056\/NEJMoa062462.","journal-title":"N Engl J Med"},{"issue":"6","key":"1460_CR30","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1517\/14740338.2015.1014799","volume":"14","author":"AJ Ellis","year":"2015","unstructured":"Ellis AJ, Hendrick VM, Williams R, Komm BS. Selective estrogen receptor modulators in clinical practice: a safety overview. Expert Opin Drug Saf. 2015;14(6):921\u201334. https:\/\/doi.org\/10.1517\/14740338.2015.1014799.","journal-title":"Expert Opin Drug Saf"},{"issue":"2 Suppl","key":"1460_CR31","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1177\/0269881107088435","volume":"22","author":"C Bushe","year":"2008","unstructured":"Bushe C, Shaw M, Peveler RC. A review of the association between antipsychotic use and hyperprolactinaemia. J Psychopharmacol. 2008;22(2 Suppl):46\u201355. https:\/\/doi.org\/10.1177\/0269881107088435.","journal-title":"J Psychopharmacol"},{"issue":"JULY","key":"1460_CR32","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1192\/BJP.181.1.49","volume":"181","author":"SM Smith","year":"2002","unstructured":"Smith SM, O\u2019Keane V, Murray R. Sexual dysfunction in patients taking conventional antipsychotic medication. Br J Psychiatry. 2002;181(JULY):49\u201355. https:\/\/doi.org\/10.1192\/BJP.181.1.49.","journal-title":"Br J Psychiatry"},{"key":"1460_CR33","doi-asserted-by":"publisher","first-page":"9516592","DOI":"10.1155\/2018\/9516592","volume":"2018","author":"MM Khan","year":"2018","unstructured":"Khan MM. Translational significance of selective estrogen receptor modulators in psychiatric disorders. Int J Endocrinol. 2018;2018:9516592. https:\/\/doi.org\/10.1155\/2018\/9516592.","journal-title":"Int J Endocrinol"},{"issue":"3","key":"1460_CR34","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1097\/YCO.0000000000000699","volume":"34","author":"BA Brand","year":"2021","unstructured":"Brand BA, de Boer JN, Sommer IEC. Estrogens in schizophrenia: progress, current challenges and opportunities. Curr Opin Psychiatry. 2021;34(3):228\u201337. https:\/\/doi.org\/10.1097\/YCO.0000000000000699.","journal-title":"Curr Opin Psychiatry"},{"issue":"10","key":"1460_CR35","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1016\/S2215-0366(21)00241-8","volume":"8","author":"H Taipale","year":"2021","unstructured":"Taipale H, Solmi M, L\u00e4hteenvuo M, Tanskanen A, Correll CU, Tiihonen J. Antipsychotic use and risk of breast cancer in women with schizophrenia: a nationwide nested case-control study in Finland. Lancet Psychiatry. 2021;8(10):883\u201391. https:\/\/doi.org\/10.1016\/S2215-0366(21)00241-8.","journal-title":"Lancet Psychiatry"},{"issue":"2 Suppl","key":"1460_CR36","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1177\/0269881107088439","volume":"22","author":"V O\u2019Keane","year":"2008","unstructured":"O\u2019Keane V. Antipsychotic-induced hyperprolactinaemia, hypogonadism and osteoporosis in the treatment of schizophrenia. J Psychopharmacol. 2008;22(2 Suppl):70\u20135. https:\/\/doi.org\/10.1177\/0269881107088439.","journal-title":"J Psychopharmacol"},{"issue":"JUNE","key":"1460_CR37","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1192\/BJP.184.6.503","volume":"184","author":"AM Meaney","year":"2004","unstructured":"Meaney AM, Smith S, Howes OD, O\u2019Brien M, Murray RM, O\u2019Keane V. Effects of long-term prolactin-raising antipsychotic medication on bone mineral density in patients with schizophrenia. Br J Psychiatry. 2004;184(JUNE):503\u20138. https:\/\/doi.org\/10.1192\/BJP.184.6.503.","journal-title":"Br J Psychiatry"},{"key":"1460_CR38","doi-asserted-by":"publisher","DOI":"10.1038\/S41467-020-18492-8","author":"D Lu","year":"2020","unstructured":"Lu D, Song J, Lu Y, et al. A shared genetic contribution to breast cancer and schizophrenia. Nat Commun. 2020. https:\/\/doi.org\/10.1038\/S41467-020-18492-8.","journal-title":"Nat Commun"},{"key":"1460_CR39","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/J.YFRNE.2017.02.003","volume":"45","author":"\u00c1L Montejo","year":"2017","unstructured":"Montejo \u00c1L, Arango C, Bernardo M, et al. Multidisciplinary consensus on the therapeutic recommendations for iatrogenic hyperprolactinemia secondary to antipsychotics. Front Neuroendocrinol. 2017;45:25\u201334. https:\/\/doi.org\/10.1016\/J.YFRNE.2017.02.003.","journal-title":"Front Neuroendocrinol"},{"issue":"20","key":"1460_CR40","doi-asserted-by":"publisher","first-page":"2291","DOI":"10.2165\/00003495-200464200-00003","volume":"64","author":"PM Haddad","year":"2004","unstructured":"Haddad PM, Wieck A. Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management. Drugs. 2004;64(20):2291\u2013314. https:\/\/doi.org\/10.2165\/00003495-200464200-00003.","journal-title":"Drugs"},{"issue":"1","key":"1460_CR41","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1038\/s41398-022-02027-4","volume":"12","author":"Z Lu","year":"2022","unstructured":"\u2022 Lu Z, Sun Y, Zhang Y, et al. Pharmacological treatment strategies for antipsychotic-induced hyperprolactinemia: a systematic review and network meta-analysis. Transl Psychiatry. 2022;12(1):267. https:\/\/doi.org\/10.1038\/s41398-022-02027-4. These comprehensive systematic review and network meta-analysis summarize studies on the efficacy of switching and adjunctive strategies for antipsychotic-induced prolactin elevation.","journal-title":"Transl Psychiatry"},{"issue":"1","key":"1460_CR42","doi-asserted-by":"publisher","first-page":"b2535","DOI":"10.1136\/bmj.b2535","volume":"339","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339(1):b2535\u2013b2535. https:\/\/doi.org\/10.1136\/bmj.b2535.","journal-title":"BMJ"},{"key":"1460_CR43","doi-asserted-by":"publisher","unstructured":"American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 4th ed. (DSM-IV). American Psychiatric Association. 1994. https:\/\/doi.org\/10.1176\/ajp.152.8.1228.","DOI":"10.1176\/ajp.152.8.1228"},{"key":"1460_CR44","unstructured":"ICD-10 Version:2010. https:\/\/icd.who.int\/browse10\/2010\/en. Accessed 23 Feb 2023."},{"issue":"3","key":"1460_CR45","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1097\/FTD.0000000000000585","volume":"41","author":"AK J\u00f6nsson","year":"2019","unstructured":"\u2022 J\u00f6nsson AK, Spigset O, Reis M. A compilation of serum concentrations of 12 antipsychotic drugs in a therapeutic drug monitoring setting. Ther Drug Monit. 2019;41(3):348\u201356. https:\/\/doi.org\/10.1097\/FTD.0000000000000585. Large therapeutic drug monitoring study showing that women have significantly higher plasma concentrations than men for most antipsychotic drugs.","journal-title":"Ther Drug Monit"},{"issue":"5","key":"1460_CR46","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1111\/acps.12794","volume":"136","author":"I Castberg","year":"2017","unstructured":"Castberg I, Westin AA, Skogvoll E, Spigset O. Effects of age and gender on the serum levels of clozapine, olanzapine, risperidone, and quetiapine. Acta Psychiatr Scand. 2017;136(5):455\u201364. https:\/\/doi.org\/10.1111\/acps.12794.","journal-title":"Acta Psychiatr Scand"},{"issue":"1","key":"1460_CR47","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1038\/s41537-021-00170-3","volume":"7","author":"S Hoekstra","year":"2021","unstructured":"Hoekstra S, Bartz-Johannessen C, Sinkeviciute I, et al. Sex differences in antipsychotic efficacy and side effects in schizophrenia spectrum disorder: results from the BeSt InTro study. NPJ Schizophr. 2021;7(1):39. https:\/\/doi.org\/10.1038\/s41537-021-00170-3.","journal-title":"NPJ Schizophr"},{"issue":"8","key":"1460_CR48","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1007\/S00228-021-03114-Z","volume":"77","author":"M Tveito","year":"2021","unstructured":"Tveito M, H\u00f8iseth G, Haslemo T, Molden E, Smith RL. Impact of age and gender on paliperidone exposure in patients after administration of long-acting injectable formulations-an observational study using blood samples from 1223 patients. Eur J Clin Pharmacol. 2021;77(8):1201\u20138. https:\/\/doi.org\/10.1007\/S00228-021-03114-Z.","journal-title":"Eur J Clin Pharmacol"},{"issue":"2","key":"1460_CR49","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","volume":"13","author":"SR Kay","year":"1987","unstructured":"Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13(2):261\u201376. https:\/\/doi.org\/10.1093\/schbul\/13.2.261.","journal-title":"Schizophr Bull"},{"key":"1460_CR50","doi-asserted-by":"publisher","DOI":"10.1016\/S0920-9964(03)00082-3","author":"MR Louz\u00e3","year":"2004","unstructured":"Louz\u00e3 MR, Marques AP, Elkis H, Bassitt D, Diegoli M, Gattaz WF. Conjugated estrogens as adjuvant therapy in the treatment of acute schizophrenia: a double-blind study. Schizophr Res. 2004. https:\/\/doi.org\/10.1016\/S0920-9964(03)00082-3.","journal-title":"Schizophr Res"},{"issue":"1","key":"1460_CR51","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41537-017-0043-3","volume":"4","author":"J de Boer","year":"2018","unstructured":"\u2022 de Boer J, Prikken M, Lei WU, Begemann M, Sommer I. The effect of raloxifene augmentation in men and women with a schizophrenia spectrum disorder: a systematic review and meta-analysis. NPJ Schizophr. 2018;4(1):1. https:\/\/doi.org\/10.1038\/s41537-017-0043-3. Comprehensive meta-analysis on the efficacy of raloxifene in schizophrenia-spectrum disorders.","journal-title":"NPJ Schizophr"},{"issue":"1","key":"1460_CR52","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s00737-017-0773-2","volume":"21","author":"Q Wang","year":"2018","unstructured":"Wang Q, Dong X, Wang Y, Li X. Raloxifene as an adjunctive treatment for postmenopausal women with schizophrenia: a meta-analysis of randomized controlled trials. Arch Womens Ment Health. 2018;21(1):31\u201341. https:\/\/doi.org\/10.1007\/s00737-017-0773-2.","journal-title":"Arch Womens Ment Health"},{"key":"1460_CR53","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.schres.2018.01.017","volume":"197","author":"XM Zhu","year":"2018","unstructured":"Zhu XM, Zheng W, Li XH, et al. Adjunctive raloxifene for postmenopausal women with schizophrenia: a meta-analysis of randomized, double-blind, placebo-controlled trials. Schizophr Res. 2018;197:288\u201393. https:\/\/doi.org\/10.1016\/j.schres.2018.01.017.","journal-title":"Schizophr Res"},{"key":"1460_CR54","doi-asserted-by":"publisher","DOI":"10.1007\/s00406-018-0938-7","author":"\u00c8 Vila","year":"2019","unstructured":"Vila \u00c8, Huerta-Ramos E, N\u00fa\u00f1ez C, Usall J, Ramos B. Specificity proteins 1 and 4 in peripheral blood mononuclear cells in postmenopausal women with schizophrenia: a 24-week double-blind, randomized, parallel, placebo-controlled trial. Eur Arch Psychiatry Clin Neurosci. 2019. https:\/\/doi.org\/10.1007\/s00406-018-0938-7.","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"issue":"2","key":"1460_CR55","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1093\/schbul\/sbv149","volume":"42","author":"J Usall","year":"2016","unstructured":"Usall J, Huerta-Ramos E, Labad J, et al. Raloxifene as an adjunctive treatment for postmenopausal women with schizophrenia: a 24-week double-blind, randomized, parallel, placebo-controlled trial. Schizophr Bull. 2016;42(2):309\u201317. https:\/\/doi.org\/10.1093\/schbul\/sbv149.","journal-title":"Schizophr Bull"},{"key":"1460_CR56","doi-asserted-by":"publisher","DOI":"10.1097\/GME.0000000000001066","author":"P Pacello","year":"2018","unstructured":"Pacello P, Baccaro LF, Pedro AO, Costa-Paiva L. Prevalence of hormone therapy, factors associated with its use, and knowledge about menopause: a population-based household survey. Menopause. 2018. https:\/\/doi.org\/10.1097\/GME.0000000000001066.","journal-title":"Menopause"},{"issue":"4","key":"1460_CR57","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1038\/nrendo.2016.164","volume":"13","author":"RA Lobo","year":"2017","unstructured":"Lobo RA. Hormone-replacement therapy: current thinking. Nat Rev Endocrinol. 2017;13(4):220\u201331. https:\/\/doi.org\/10.1038\/nrendo.2016.164.","journal-title":"Nat Rev Endocrinol"},{"key":"1460_CR58","doi-asserted-by":"publisher","DOI":"10.1016\/S0920-9964(00)00088-8","author":"J Kulkarni","year":"2001","unstructured":"Kulkarni J, Riedel A, de Castella AR, et al. Estrogen - a potential treatment for schizophrenia. Schizophr Res. 2001. https:\/\/doi.org\/10.1016\/S0920-9964(00)00088-8.","journal-title":"Schizophr Res"},{"issue":"6","key":"1460_CR59","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1016\/S0278-5846(03)00161-1","volume":"27","author":"S Akhondzadeh","year":"2003","unstructured":"Akhondzadeh S, Nejatisafa AA, Amini H, et al. Adjunctive estrogen treatment in women with chronic schizophrenia: a double-blind, randomized, and placebo-controlled trial. Prog Neuropsychopharmacol Biol Psychiatry. 2003;27(6):1007\u201312. https:\/\/doi.org\/10.1016\/S0278-5846(03)00161-1.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"8","key":"1460_CR60","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1001\/ARCHPSYC.65.8.955","volume":"65","author":"J Kulkarni","year":"2008","unstructured":"Kulkarni J, de Castella A, Fitzgerald PB, et al. Estrogen in severe mental illness: a potential new treatment approach. Arch Gen Psychiatry. 2008;65(8):955\u201360. https:\/\/doi.org\/10.1001\/ARCHPSYC.65.8.955.","journal-title":"Arch Gen Psychiatry"},{"issue":"4","key":"1460_CR61","doi-asserted-by":"publisher","first-page":"172","DOI":"10.3371\/CSRP.GHFA.01062013","volume":"6","author":"E Ghafari","year":"2013","unstructured":"Ghafari E, Fararouie M, Shirazi HG, Farhangfar A, Ghaderi F, Mohammadi A. Combination of estrogen and antipsychotics in the treatment of women with chronic schizophrenia: a double-blind, randomized, placebo-controlled clinical trial. Clin Schizophr Relat Psychoses. 2013;6(4):172\u20136. https:\/\/doi.org\/10.3371\/CSRP.GHFA.01062013.","journal-title":"Clin Schizophr Relat Psychoses"},{"issue":"6","key":"1460_CR62","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1038\/mp.2014.33","volume":"20","author":"J Kulkarni","year":"2015","unstructured":"Kulkarni J, Gavrilidis E, Wang W, et al. Estradiol for treatment-resistant schizophrenia: a large-scale randomized-controlled trial in women of child-bearing age. Mol Psychiatry. 2015;20(6):695\u2013702. https:\/\/doi.org\/10.1038\/mp.2014.33.","journal-title":"Mol Psychiatry"},{"key":"1460_CR63","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2019.1842","author":"M Weiser","year":"2019","unstructured":"Weiser M, Levi L, Zamora D, et al. Effect of adjunctive estradiol on schizophrenia among women of childbearing age: a randomized clinical trial. JAMA Psychiat. 2019. https:\/\/doi.org\/10.1001\/jamapsychiatry.2019.1842.","journal-title":"JAMA Psychiat"},{"issue":"8","key":"1460_CR64","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1016\/j.psyneuen.2010.01.014","volume":"35","author":"J Kulkarni","year":"2010","unstructured":"Kulkarni J, Gurvich C, Lee SJ, et al. Piloting the effective therapeutic dose of adjunctive selective estrogen receptor modulator treatment in postmenopausal women with schizophrenia. Psychoneuroendocrinology. 2010;35(8):1142\u20137. https:\/\/doi.org\/10.1016\/j.psyneuen.2010.01.014.","journal-title":"Psychoneuroendocrinology"},{"issue":"11","key":"1460_CR65","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.4088\/JCP.10m06610","volume":"72","author":"J Usall","year":"2011","unstructured":"Usall J, Huerta-Ramos E, Iniesta R, et al. Raloxifene as an adjunctive treatment for postmenopausal women with schizophrenia: a double-blind, randomized, placebo-controlled trial. J Clin Psychiatry. 2011;72(11):1552\u20137. https:\/\/doi.org\/10.4088\/JCP.10m06610.","journal-title":"J Clin Psychiatry"},{"key":"1460_CR66","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/2008-2231-22-55","volume":"22","author":"G Kianimehr","year":"2014","unstructured":"Kianimehr G, Fatehi F, Hashempoor S, et al. Raloxifene adjunctive therapy for postmenopausal women suffering from chronic schizophrenia: a randomized double-blind and placebo controlled trial. Daru. 2014;22:55. https:\/\/doi.org\/10.1186\/2008-2231-22-55.","journal-title":"Daru"},{"issue":"6","key":"1460_CR67","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1038\/mp.2015.11","volume":"20","author":"TW Weickert","year":"2015","unstructured":"Weickert TW, Weinberg D, Lenroot R, et al. Adjunctive raloxifene treatment improves attention and memory in men and women with schizophrenia. Mol Psychiatry. 2015;20(6):685\u201394. https:\/\/doi.org\/10.1038\/mp.2015.11.","journal-title":"Mol Psychiatry"},{"issue":"9","key":"1460_CR68","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1001\/jamapsychiatry.2016.1383","volume":"73","author":"J Kulkarni","year":"2016","unstructured":"Kulkarni J, Gavrilidis E, Gwini SM, et al. Effect of adjunctive raloxifene therapy on severity of refractory schizophrenia in women. JAMA Psychiat. 2016;73(9):947. https:\/\/doi.org\/10.1001\/jamapsychiatry.2016.1383.","journal-title":"JAMA Psychiat"},{"issue":"7","key":"1460_CR69","doi-asserted-by":"publisher","first-page":"e758","DOI":"10.4088\/JCP.15m10498","volume":"78","author":"M Weiser","year":"2017","unstructured":"Weiser M, Levi L, Burshtein S, et al. Raloxifene plus antipsychotics versus placebo plus antipsychotics in severely ill decompensated postmenopausal women with schizophrenia or schizoaffective disorder: a randomized controlled trial. J Clin Psychiatry. 2017;78(7):e758\u201365. https:\/\/doi.org\/10.4088\/JCP.15m10498.","journal-title":"J Clin Psychiatry"},{"key":"1460_CR70","doi-asserted-by":"publisher","unstructured":"\u2022 Zhang L, Qi H, Xie YY, et al. Efficacy and safety of adjunctive aripiprazole, metformin, and paeoniae-glycyrrhiza decoction for antipsychotic-induced hyperprolactinemia: a network meta-analysis of randomized controlled trials. Front Psychiatry. 2021;12. https:\/\/doi.org\/10.3389\/FPSYT.2021.728204. Network meta-analysis comparing the efficacy and safety of adjunctive therapies for correcting antipsychotic-induced elevated prolactin levels.","DOI":"10.3389\/FPSYT.2021.728204"},{"key":"1460_CR71","doi-asserted-by":"publisher","DOI":"10.3389\/FNMOL.2022.892477","author":"C Zhu","year":"2022","unstructured":"Zhu C, Li R, Ju M, et al. Metformin in the treatment of amisulpride-induced hyperprolactinemia: a clinical Trial. Front Mol Neurosci. 2022. https:\/\/doi.org\/10.3389\/FNMOL.2022.892477.","journal-title":"Front Mol Neurosci"},{"issue":"4","key":"1460_CR72","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1517\/17425255.4.4.413","volume":"4","author":"MJ Scandlyn","year":"2008","unstructured":"Scandlyn MJ, Stuart EC, Rosengren RJ. Sex-specific differences in CYP450 isoforms in humans. Expert Opin Drug Metab Toxicol. 2008;4(4):413\u201324. https:\/\/doi.org\/10.1517\/17425255.4.4.413.","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"2","key":"1460_CR73","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1124\/DMD.112.046276","volume":"41","author":"SY Choi","year":"2013","unstructured":"Choi SY, Koh KH, Jeong H. Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013;41(2):263\u20139. https:\/\/doi.org\/10.1124\/DMD.112.046276.","journal-title":"Drug Metab Dispos"},{"issue":"01\/02","key":"1460_CR74","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1055\/s-0043-116492","volume":"51","author":"C Hiemke","year":"2018","unstructured":"Hiemke C, Bergemann N, Clement H, et al. Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017. Pharmacopsychiatry. 2018;51(01\/02):9\u201362. https:\/\/doi.org\/10.1055\/s-0043-116492.","journal-title":"Pharmacopsychiatry"},{"issue":"1","key":"1460_CR75","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s13293-020-00308-5","volume":"11","author":"I Zucker","year":"2020","unstructured":"\u2022 Zucker I, Prendergast BJ. Sex differences in pharmacokinetics predict adverse drug reactions in women. Biol Sex Differ. 2020;11(1):32. https:\/\/doi.org\/10.1186\/s13293-020-00308-5. This article summarizes sex differences in pharmacokinetics of diverse types of medications and provides valuable insights on how these differences predict adverse drug reactions in women.","journal-title":"Biol Sex Differ"},{"issue":"4","key":"1460_CR76","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1016\/S2215-0366(21)00383-7","volume":"9","author":"BA Brand","year":"2022","unstructured":"Brand BA, de Boer JN, Dazzan P, Sommer IE. Towards better care for women with schizophrenia-spectrum disorders. Lancet Psychiatry. 2022;9(4):330\u20136. https:\/\/doi.org\/10.1016\/S2215-0366(21)00383-7.","journal-title":"Lancet Psychiatry"},{"issue":"3","key":"1460_CR77","doi-asserted-by":"publisher","first-page":"3649","DOI":"10.4088\/JCP.19CS13169","volume":"81","author":"G Schoretsanitis","year":"2020","unstructured":"\u2022 Schoretsanitis G, Kane JM, Correll CU, et al. Blood levels to optimize antipsychotic treatment in clinical practice: a joint consensus statement of the American Society of Clinical Psychopharmacology and the Therapeutic Drug Monitoring Task Force of the Arbeitsgemeinschaft f\u00fcr Neuropsychopharmakologie und Pharmakopsychiatrie. J Clin Psychiatry. 2020;81(3):3649. https:\/\/doi.org\/10.4088\/JCP.19CS13169. This consensus statement summarizes essential information on the routine use of TDM for antipsychotics which can be used to perform TDM as part of the clinical decision-making process.","journal-title":"J Clin Psychiatry"}],"updated-by":[{"DOI":"10.1007\/s11920-024-01520-5","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2024,7,18]],"date-time":"2024-07-18T00:00:00Z","timestamp":1721260800000}}],"container-title":["Current Psychiatry Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11920-023-01460-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11920-023-01460-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11920-023-01460-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,18]],"date-time":"2024-07-18T05:07:05Z","timestamp":1721279225000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11920-023-01460-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,21]]},"references-count":77,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["1460"],"URL":"https:\/\/doi.org\/10.1007\/s11920-023-01460-6","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s11920-024-01520-5","asserted-by":"object"}]},"ISSN":["1523-3812","1535-1645"],"issn-type":[{"value":"1523-3812","type":"print"},{"value":"1535-1645","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,21]]},"assertion":[{"value":"13 September 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 July 2024","order":3,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":4,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":5,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s11920-024-01520-5","URL":"https:\/\/doi.org\/10.1007\/s11920-024-01520-5","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}]}}